Your browser doesn't support javascript.
loading
Prognostic value of transcriptional expression of fibronectin type III domain-containing 4 (FNDC4) in head and neck carcinoma patients treated with chemoradiotherapy
Camacho, Mercedes; León, Xabier; Pujol, Albert; Montezuma, Laura; Quer, Miguel; García, Jacinto.
Afiliação
  • Camacho, Mercedes; Research Institute Hospital Sant Pau. Barcelona. Spain
  • León, Xabier; Hospital de la Santa Creu i Sant Pau. Barcelona. Spain
  • Pujol, Albert; Hospital de la Santa Creu i Sant Pau. Barcelona. Spain
  • Montezuma, Laura; Hospital de la Santa Creu i Sant Pau. Barcelona. Spain
  • Quer, Miguel; Hospital de la Santa Creu i Sant Pau. Barcelona. Spain
  • García, Jacinto; Hospital del Mar. Barcelona. Spain
Clin. transl. oncol. (Print) ; 24(11): 2175-2180, noviembre 2022. graf
Artigo em Inglês | IBECS | ID: ibc-210145
Biblioteca responsável: ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
FNDC4 gene encodes the fibronectin type III domain-containing 4 protein. Elevated expression of FNDC4 has been associated with poor prognosis in several types of cancer. There are no studies that have evaluated the prognostic capacity of FNDC4 in patients with head and neck cancer (HNSCC). The aim of our study was to analyze the relationship between the transcriptional expression of FNDC4 and prognosis in HNSCC patients.MethodsWe determined the transcriptional expression of FNDC4 in 67 patients with advanced-stage HNSCC (III–IV) treated with chemoradiotherapy. The FNDC4 expression was categorized according to the disease-specific survival with a recursive partitioning analysis.ResultsThere were significant differences in disease-specific survival as a function of the level of FNDC4 transcriptional expression. The 5-year disease-specific survival for patients with high FNDC4 expression (n = 44, 65.7%) was 32.9% (95% CI 16.5–49.3%), and for patients with low expression (n = 23, 34.3%) it was 85.4% (95% CI 70.2–100%) (P = 0.0001). Patients with a high FNDC4 expression had poorer local (P = 0.097), regional (P = 0.008), and distant (0.034) recurrence-free survival. The results of a multivariate analysis showed that patients with a high FNDC4 expression had a 6.15-fold increased risk of death as a consequence of the HNSCC (95% CI 1.71–22.06).ConclusionFNCF4 transcriptional expression was significantly related to the disease-specific survival of HNSCC patients treated with chemoradiotherapy. Patients with elevated FNDC4 expression had a significant decrease in disease-specific survival. (AU)
Assuntos


Texto completo: Disponível Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Carcinoma de Células Escamosas / Quimiorradioterapia / Domínio de Fibronectina Tipo III / Carcinoma de Células Escamosas de Cabeça e Pescoço / Neoplasias de Cabeça e Pescoço Limite: Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2022 Tipo de documento: Artigo Instituição/País de afiliação: Hospital de la Santa Creu i Sant Pau/Spain / Hospital del Mar/Spain / Research Institute Hospital Sant Pau/Spain

Texto completo: Disponível Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Carcinoma de Células Escamosas / Quimiorradioterapia / Domínio de Fibronectina Tipo III / Carcinoma de Células Escamosas de Cabeça e Pescoço / Neoplasias de Cabeça e Pescoço Limite: Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2022 Tipo de documento: Artigo Instituição/País de afiliação: Hospital de la Santa Creu i Sant Pau/Spain / Hospital del Mar/Spain / Research Institute Hospital Sant Pau/Spain
...